In patients, these melanomas are mostly treated with combination therapy based on the use of BRAF/MEK inhibitors, but the duration of response is variable and patients frequently experience recurrence: new treatment strategies, especially different combinations, are therefore needed. The gene discussed is MAP2K7; the disease is melanoma.